Results 1 to 10 of about 5,784 (166)

Activation of AMPK sensitizes medulloblastoma to Vismodegib and overcomes Vismodegib-resistance [PDF]

FASEB BioAdvances, 2021
Vismodegib, a Smoothened antagonist, is clinically approved for treatment of human basal cell carcinoma (BCC), in the clinical trials of medulloblastoma (MB) and other cancers.
Silpa Gampala, GuangJun Zhang, Jer-Yen Yang   +2 more
exaly   +3 more sources

Benefit–risk assessment of sonidegib and vismodegib in the treatment of locally advanced basal cell carcinoma [PDF]

Drugs in Context, 2022
Background: Sonidegib and vismodegib are Hedgehog pathway inhibitors (HhIs) that play a relevant role in the management of locally advanced basal cell carcinoma (laBCC).
Antonio J García Ruiz, Nuria García-Agua Soler, Enrique Herrera Acosta, Iris Zalaudek, Josep Malvehy   +4 more
doaj   +2 more sources

Vismodegib suppresses TRAIL-mediated liver injury in a mouse model of nonalcoholic steatohepatitis. [PDF]

PLoS ONE, 2013
Hedgehog signaling pathway activation has been implicated in the pathogenesis of NASH. Despite this concept, hedgehog pathway inhibitors have not been explored. Thus, we examined the effect of vismodegib, a hedgehog signaling pathway inhibitor, in a diet-
Petra Hirsova, Samar H Ibrahim, Steven F Bronk, Hideo Yagita, Gregory J Gores   +4 more
doaj   +2 more sources

Vismodegib Exerts a Pleotropic Effect on Topotecan-Resistant and Sensitive Ovarian Cancer Cell Lines in 2D and 3D Cell Culture Models [PDF]

Molecules
Ovarian cancer remains a leading cause of gynecological cancer-related mortality. Although the standard therapy is usually effective at first, the development of multidrug resistance (MDR) significantly limits the efficacy of the treatment.
Piotr Stasiak, Justyna Sopel, Artur Płóciennik, Julia Maria Lipowicz, Agnieszka Anna Rawłuszko-Wieczorek, Karolina Sterzyńska, Monika Świerczewska, Jan Korbecki, Radosław Januchowski   +8 more
doaj   +2 more sources

Real-World Treatment Patterns of Patients with Basal Cell Carcinoma Using Sonidegib and Vismodegib: Discontinuation Rates and Clinical Conditions During Treatment [PDF]

Dermatology and Therapy
Introduction Sonidegib and vismodegib are Hedgehog pathway inhibitors (HHIs) approved for the treatment of locally advanced basal cell carcinoma (laBCC), as well as metastatic basal cell carcinoma (mBCC) for vismodegib.
Mark G. Lebwohl, Darrell S. Rigel, Zeynep Eroglu, Victoria E. Barghout, Deepshekhar Gupta, Enrico Zanardo, Lynn Huynh, Mihran A. Yenikomshian, Nicholas Squittieri, Thomas J. Ferro, Kunal Patel   +10 more
doaj   +2 more sources

Disproportionality analysis comparing safety profiles of sonidegib and vismodegib based on the FAERS database [PDF]

Scientific Reports
This study aims to comprehensively evaluate the long-term safety profiles of hedgehog pathway inhibitors (HPIs), sonidegib and vismodegib, which have been approved for basal cell carcinoma but lack extensive real-world safety data.
Zhixing Zheng, Zhengeng Wang, Qinghui Guo, Xiang Chen, Shuting Shen, Lixin Zhang, Enwen Lu, Zhanfa Ma, Donghui Chen   +8 more
doaj   +2 more sources

Cranial base synostosis in mice caused by upregulation of Wnt following partial inhibition of Shh [PDF]

BMC Biology
Background The cranial base develops from multipotent mesenchymal cells through endochondral ossification. Genetic ablation of Sonic hedgehog (Shh) or Smoothened (Smo) leads to early apoptosis of cranial base cells, thus limiting the study of their role ...
Jiangping Chen, Chengyan Ren, Chuanqing Mao, Yongzhen Lai, Meng Lu, Yuanjing Jiang, Weihui Chen   +6 more
doaj   +2 more sources

Real-world assessment and treatment of locally advanced basal cell carcinoma: Findings from the RegiSONIC disease registry

PLoS ONE, 2022
Background Limited information is available regarding real-world treatment patterns and their effectiveness and safety in patients with locally advanced basal cell carcinoma, including patients not typically represented in clinical trials. The purpose of
Aleksandar Sekulic, Simon Yoo, Ragini Kudchadkar, Julie Guillen, Gary Rogers, Anne Lynn S. Chang, Scott Guenthner, Bernard Raskin, Keith Dawson, Yong Mun, Laura Chu, Edward McKenna, Mario Lacouture   +12 more
doaj   +2 more sources

Vismodegib in neoadjuvant treatment of locally advanced basal cell carcinoma: First results of a multicenter, open-label, phase 2 trial (VISMONEO study)

EClinicalMedicine, 2021
Background: Surgery is the primary treatment for basal cell carcinoma (BCC). In locally advanced basal cell carcinoma (laBCC), surgery may cause functional or aesthetic damage.
Nicolas Bertrand, MD, Pierre Guerreschi, MD, PhD, Nicole Basset-Seguin, MD, PhD, Philippe Saiag, MD, PhD, Alain Dupuy, MD, PhD, Sophie Dalac-Rat, MD, Véronique Dziwniel, PhD, César Depoortère, MD, Alain Duhamel, MD, PhD, Laurent Mortier, MD, PhD   +9 more
doaj   +1 more source

Inhibition of CAL27 Oral Squamous Carcinoma Cell by Targeting Hedgehog Pathway With Vismodegib or Itraconazole

Frontiers in Oncology, 2020
Oral Squamous Cell Carcinoma (OSCC) presents an important challenge for the health systems worldwide. Thus, unraveling the biological mechanisms involved in OSCC pathogenesis is essential to the discovery of new drugs with anticancer potential.
Raíza Dias Freitas, Raíza Dias Freitas, Rosane Borges Dias, Rosane Borges Dias, Manuela Torres Andion Vidal, Manuela Torres Andion Vidal, Ludmila de Faro Valverde, Ludmila de Faro Valverde, Rafaela Gomes Alves Costa, Andresa Karen Andrade Damasceno, Caroline Brandi Schlaepfer Sales, Leonardo de Oliveira Siquara da Rocha, Mitermayer Galvão dos Reis, Mitermayer Galvão dos Reis, Milena Botelho Pereira Soares, Ricardo Della Coletta, Thiago Almeida Pereira, Daniel Pereira Bezerra, Clarissa Araújo Gurgel Rocha, Clarissa Araújo Gurgel Rocha, Clarissa Araújo Gurgel Rocha   +20 more
doaj   +1 more source